IREN Founder-CEO RSU Award: Scale, Accounting and Governance

Bottom line

IREN granted 9,099,328 restricted stock units to each co-founder/co-CEO, or 18,198,656 RSUs combined, effective July 1, 2026. This is an extraordinary, outlier-sized public-company compensation award—closer to a founder recapitalization or special retention package than normal annual executive pay.

Scale and dilution

Measure	Approximate amount
RSUs per co-CEO	9.10M
Combined RSUs	18.20M
Value per co-CEO at July 1 close of $43.32	$394M
Combined grant-date headline value	$788M
Combined value at $41.575 on August 4	$757M
Incremental share-count dilution	~4.9% before issuance; ~4.7% of the post-award company

IREN reported 357.38M ordinary shares outstanding at April 30, 2026. Including approximately 12.6M shares issued at the August 2026 Mirantis closing produces roughly 370.0M shares before this award and 388.2M after it. At $41.575, that is approximately $16.1B of founder-award-adjusted equity value.Holding enterprise value constant, the award alone reduces per-share value by roughly 5%. It is noncash compensation, but the ownership transfer is economically real.

Terms

• Four equal annual vesting tranches over four years, subject to continued employment.
• Each vested tranche is locked for a further two years; the final tranche cannot be monetized until fiscal 2033.
• Neither co-CEO is expected to receive another equity incentive grant until fiscal 2031.
• The award has service conditions but no ARR, ROIC, free-cash-flow, earnings or per-share-value hurdle.
• The board says the purpose is founder retention through IREN's critical AI infrastructure buildout.

Sources: IREN Form 8-K, July 1, 2026 and independent chair's shareholder letter.

Accounting treatment

The award was granted after IREN's June 30 fiscal year-end, so it was not absorbed in FY2026 results. Expense begins in FY2027 Q1, ending September 30, 2026.IREN will:

• Measure equity-classified RSUs at grant-date fair value.
• Apply an independently determined discount for the two-year post-vesting transfer restriction.
• Recognize noncash stock compensation in SG&A and additional paid-in capital.
• Expense each vesting tranche separately, which front-loads the charge.
• Exclude the expense from adjusted EBITDA, while including it in GAAP operating income, net income and EPS.

Before the holding-period valuation discount, the approximate recognition pattern would be:

Fiscal year	Share of total expense	Undiscounted amount
FY2027	52.1%	~$411M
FY2028	27.1%	~$214M
FY2029	14.6%	~$115M
FY2030	6.3%	~$49M

The precise accounting fair value will be disclosed in the proxy. See IREN's stock-compensation policy and existing award disclosures.

Is this normal?

No—not as ordinary public-company executive compensation. Large founder retention awards exist, but the combination here is exceptional:

• Approximately 5% incremental dilution for two executives.
• Roughly $0.8B of unrestricted headline value at grant.
• Two recipients rather than one.
• Purely time-based vesting.
• Existing founder super-voting influence.
• Additional substantial 2025 awards and FY2025 reported compensation of approximately $72.6M per co-CEO.

The mitigating features are the four-year vest, additional two-year holding restriction, exposure to share-price declines, forfeiture upon premature departure, and the stated pause in new equity grants until FY2031. Those features improve retention alignment but do not make the magnitude routine or convert the award into performance-based compensation.

Investor interpretation

This is not a cash-liquidity problem and does not invalidate IREN's operating assets or contracts. It is a material dilution and governance event. A shareholder can reasonably:

1. Reduce unchanged per-share valuation by approximately 5%.
2. Apply an additional governance discount or higher required return.
3. Monitor whether future growth is financed per share rather than merely in aggregate.
4. Treat the absence of explicit performance hurdles as the central weakness of the award.